Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design.

[1]  Dafydd R Owen,et al.  Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis. , 2009, Bioorganic & medicinal chemistry letters.

[2]  C. Laurence,et al.  The pK(BHX) database: toward a better understanding of hydrogen-bond basicity for medicinal chemists. , 2009, Journal of medicinal chemistry.

[3]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[4]  J. Adams,et al.  Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. , 2009, The Biochemical journal.

[5]  T. Kenakin.  Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect. , 2009, ACS chemical biology.

[6]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[7]  J. Lyons,et al.  Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines , 2009, Molecular Cancer Therapeutics.

[8]  C. Hunter,et al.  Evidence for partially bound states in cooperative molecular recognition interfaces. , 2008, Journal of the American Chemical Society.

[9]  E. Freire.  Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.

[10]  Arup K. Ghose,et al.  Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. , 2008, Journal of medicinal chemistry.

[11]  Paul G Wyatt,et al.  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.

[12]  E. Lunney,et al.  Targeting the unactivated conformations of protein kinases for small molecule drug discovery , 2008, Expert opinion on drug discovery.

[13]  J. Chaires,et al.  Calorimetry and thermodynamics in drug design. , 2008, Annual review of biophysics.

[14]  Yvonne C. Martin,et al.  Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..

[15]  R. Copeland,et al.  Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.

[16]  Ian A. Watson,et al.  Chemical fragments as foundations for understanding target space and activity prediction. , 2008, Journal of medicinal chemistry.

[17]  S. Bembenek,et al.  Ligand binding efficiency: trends, physical basis, and implications. , 2008, Journal of medicinal chemistry.

[18]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[19]  Arun K. Ghosh,et al.  Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. , 2007, Bioorganic & medicinal chemistry.

[20]  B. Nordén,et al.  Enthalpy-entropy compensation: a phantom or something useful? , 2007, The journal of physical chemistry. B.

[21]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[22]  K. Hertogs,et al.  Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier , 2007, Journal of Virology.

[23]  G. Vauquelin,et al.  Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation , 2007, Neurochemistry International.

[24]  M. Verdonk,et al.  A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. , 2007, Current topics in medicinal chemistry.

[25]  M. Gilson,et al.  Calculation of protein-ligand binding affinities. , 2007, Annual review of biophysics and biomolecular structure.

[26]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[27]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2006, Nature Reviews Drug Discovery.

[28]  P. Seeman.  Targeting the dopamine D2 receptor in schizophrenia , 2006, Expert opinion on therapeutic targets.

[29]  G. Vauquelin,et al.  Slow antagonist dissociation and long-lasting in vivo receptor protection. , 2006, Trends in pharmacological sciences.

[30]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[31]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[32]  E. Freire,et al.  Overcoming Roadblocks in Lead Optimization: A Thermodynamic Perspective , 2006, Chemical biology & drug design.

[33]  P. Dorr,et al.  Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. , 2005, Biochemical pharmacology.

[34]  Jon Read,et al.  Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase. , 2005, Biochemistry.

[35]  E. Freire,et al.  Binding thermodynamics of statins to HMG-CoA reductase. , 2005, Biochemistry.

[36]  E. Freire,et al.  Adaptive inhibitors of the HIV-1 protease. , 2005, Progress in biophysics and molecular biology.

[37]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[38]  Eric Westhof,et al.  Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Velázquez‐Campoy,et al.  Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets. , 2004, The international journal of biochemistry & cell biology.

[40]  D. Swinney,et al.  Biochemical mechanisms of drug action: what does it take for success? , 2004, Nature Reviews Drug Discovery.

[41]  Tudor I. Oprea,et al.  Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.

[42]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[43]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[44]  C. Pargellis,et al.  The kinetics of binding to p38MAP kinase by analogues of BIRB 796. , 2003, Bioorganic & medicinal chemistry letters.

[45]  G. Evans,et al.  Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase* , 2003, Journal of Biological Chemistry.

[46]  P. Blower.  Granisetron: relating pharmacology to clinical efficacy , 2003, Supportive Care in Cancer.

[47]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[48]  Wesley Schaal,et al.  Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. , 2002, Journal of medicinal chemistry.

[49]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[50]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[51]  M. Billah,et al.  Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. , 2002, European journal of pharmacology.

[52]  A. Gradman.  AT1-receptor blockers: differences that matter , 2002, Journal of Human Hypertension.

[53]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[54]  U. Norinder,et al.  Computational approaches to the prediction of the blood-brain distribution. , 2002, Advanced drug delivery reviews.

[55]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[56]  G. Vauquelin,et al.  Tight binding of the angiotensin AT1 receptor antagonist [3H]candesartan is independent of receptor internalization , 2001 .

[57]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[58]  J. V. van Noord,et al.  A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease , 2000 .

[59]  Pickett,et al.  Computational methods for the prediction of 'drug-likeness' , 2000, Drug discovery today.

[60]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[61]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[62]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[63]  T. Witek,et al.  Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. , 1999, Life sciences.

[64]  S. Akuzawa,et al.  Comparative study of [3H]ramosetron and [3H]granisetron binding in the cloned human 5-hydroxytryptamine3 receptors. , 1998, Japanese journal of pharmacology.

[65]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[66]  B Honig,et al.  Extracting hydrophobic free energies from experimental data: relationship to protein folding and theoretical models. , 1991, Biochemistry.

[67]  Vincenzo Mollica,et al.  Group contributions to the thermodynamic properties of non-ionic organic solutes in dilute aqueous solution , 1981 .

[68]  C. Pfeiffer.  Optical isomerism and pharmacological action, a generalization. , 1956, Science.

[69]  Stuart L. Schreiber,et al.  Chemical biology : from small molecules to systems biology and drug design , 2007 .

[70]  L. M. Lima,et al.  Bioisosterism: a useful strategy for molecular modification and drug design. , 2005, Current medicinal chemistry.

[71]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.

[72]  Michael H. Abraham,et al.  Hydrogen bonding. Part 9. Solute proton donor and proton acceptor scales for use in drug design , 1989 .

[73]  P. Andrews,et al.  Functional group contributions to drug-receptor interactions. , 1984, Journal of medicinal chemistry.